We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Human CRP-Levels Compared Using Point-of-Care Methods

By LabMedica International staff writers
Posted on 08 Oct 2019
Due to the rapid increase of the C-reactive protein (CRP) concentration in the event of an inflammatory disease, CRP is regarded as one of the most important acute phase proteins. More...
Inflammation and CRP play an important role in operations, trauma, mental stress, myocardial infarction and neoplastic diseases.

The use of point-of-care (POC) methods and the measurements of CRP as a diagnostic marker have both increased over the past years. This has led to an increase in POC-methods analyzing CRP. High CRP levels are often seen as an indication for the proscribing of antibiotics. The quality of POC-systems compared to routine diagnostic measurements for the analysis of CRP is thereby of major importance, since many small practices will use POC-methods.

Biomedical scientists from the Salzburg University of Applied Sciences (Puch bei Hallein, Austria) compared POC and classical clinical chemistry methods, using 199 anonymized patient samples (104 male and 95 female patients aged from 31 to 96 years). The blood samples were selected based on a CRP concentration of more than 100 mg/L as measured by the Architect ci8200SR.

Comparisons were then made with ABX Micros CRP 200 (Horiba, Kyoto, Japan) and the i-CHROMA system. The CRP-levels on the Architect ci8200 were detected using serum samples and the method is based on a turbidimetric assay. EDTA-whole blood was used for the test procedure with the i-CHROMA and ABX. The ABX also works with a turbidimetric assay system and the i-CHROMA is based on a fluorescence sandwich immunoassay. The values from the i-CHROMA were used corrected for the hematocrit values.

The scientists reported that the results of the Architect ci8200 and the ABX showed significant differences when compared to the results of the i-CHROMA with hematocrit corrections. In addition, the values of the Architect ci8200 and the ABXs were also significantly different. Nevertheless, the most pronounced differences were seen when comparing the i-CHROMA with the Architect ci8200 with detected differences of up to 147.6 mg/L. Comparing the values of the i-CHROMA with the ABX resulted in differences of up to 92.7 mg/L. The lowest maximal difference of 39.4 mg/L is seen when comparing the results of the Architect ci8200 and the ABX.

The authors concluded that the measured CRP concentrations of the i-CHROMA strongly differ in the higher CRP concentration range when compared to the measurements performed on routine diagnostic equipment. The significantly reduced CRP measurements can strongly affect patient safety and result in wrong diagnostic measures. The study was published on September 19, 2019, in the journal Practical Laboratory Medicine.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.